公开(公告)号：US11873361B2

公开(公告)日：2024-01-16

申请号：US17836282

申请日：2022-06-09

申请人： Bausch + Lomb Ireland Limited

发明人： Alok Kumar Awasthi ,  Kristen Rae Hovinga ,  Emily Abrams Gabriel ,  Kevin Jacob DeRyke ,  Jade J. Russell ,  James Anthony DiBella, Jr. ,  Alana Ingham

IPC分类号： C08F283/06 ,  A61L27/16 ,  A61L27/50 ,  C08F226/10 ,  C08F283/12 ,  C08K5/18 ,  C08K5/42 ,  G02B1/04

CPC分类号： C08F283/06 ,  A61L27/16 ,  A61L27/50 ,  C08F226/10 ,  C08F283/12 ,  C08K5/18 ,  C08K5/42 ,  A61L2430/16 ,  G02B1/043

摘要： An ophthalmic device for slowing, inhibiting or preventing myopia progression which is a polymerization product of a monomeric mixture comprising (a) greater than 50 wt. %, based on the total weight of the monomeric mixture, of one or more non-silicone-containing hydrophilic monomers; (b) one or more crosslinking agents; and (c) one or more red-light blocking compounds blocking greater than 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nm to about 800 nm, wherein the one or more red-light blocking compounds have one or more ethylenically unsaturated reactive end groups.

公开(公告)号：US20230097637A1

公开(公告)日：2023-03-30

申请号：US17836258

申请日：2022-06-09

申请人： Bausch + Lomb Ireland Limited

发明人： Alok Kumar Awasthi ,  Kristen Rae Hovinga ,  Emily Abrams Gabriel ,  Kevin Jacob DeRyke ,  Jade J. Russell ,  Alana Ingham

IPC分类号： G02C7/10 ,  G02C7/04 ,  A61L12/14 ,  C07D279/08 ,  C07C301/02 ,  C07D205/06 ,  C07D409/06 ,  C07D403/10 ,  C07D403/14

摘要： A method for preparing an ophthalmic device for slowing, inhibiting or preventing myopia progression involves (a) soaking an ophthalmic device in one or more first solvent solutions to swell the ophthalmic device; (b) soaking the swelled ophthalmic device in one or more second solvents solutions comprising one or more red-light blocking compounds blocking greater than about 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nanometers (nm) to about 800 nm to de-swell the swelled ophthalmic device and entrap the one or more red-light blocking compounds in the de-swelled ophthalmic device; and (c) sterilizing the de-swelled ophthalmic device.

公开(公告)号：US20230096315A1

公开(公告)日：2023-03-30

申请号：US17836299

申请日：2022-06-09

申请人： Bausch + Lomb Ireland Limited

发明人： Alok Kumar Awasthi ,  Kristen Rae Hovinga ,  Emily Abrams Gabriel ,  Kevin Jacob DeRyke ,  Jade J. Russell

IPC分类号： C08F126/10 ,  A61L27/50 ,  C08J7/14 ,  C09B62/83

摘要： A method for preparing an ophthalmic device for slowing, inhibiting or preventing myopia progression involves contacting an ophthalmic device having one or more reactive functional groups with one or more red-light blocking compounds having one or more reactive functional groups complementary to the one or more reactive functional groups of the ophthalmic device in a basic solution for a time period sufficient to covalently bond at least one reactive functional group of the ophthalmic device with at least one reactive functional group of the one or more red-light blocking compounds. The one or more red-light blocking compounds block greater than about 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nanometers (nm) to about 800 nm.

公开(公告)号：US20230089707A1

公开(公告)日：2023-03-23

申请号：US17836282

申请日：2022-06-09

申请人： Bausch + Lomb Ireland Limited

发明人： Alok Kumar Awasthi ,  Kristen Rae Hovinga ,  Emily Abrams Gabriel ,  Kevin Jacob DeRyke ,  Jade J. Russell ,  James Anthony DiBella, JR. ,  Alana Ingham

IPC分类号： C08F283/06 ,  A61L27/50 ,  A61L27/16 ,  C08F283/12 ,  C08K5/42 ,  C08K5/18 ,  C08F226/10

摘要： An ophthalmic device for slowing, inhibiting or preventing myopia progression which is a polymerization product of a monomeric mixture comprising (a) greater than 50 wt. %, based on the total weight of the monomeric mixture, of one or more non-silicone-containing hydrophilic monomers; (b) one or more crosslinking agents; and (c) one or more red-light blocking compounds blocking greater than 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nm to about 800 nm, wherein the one or more red-light blocking compounds have one or more ethylenically unsaturated reactive end groups.